The European Drug Administration (EMA) has approved the introduction of the world's first malaria vaccine called Mosquirix in Africa.
According to WHO experts, tens of thousands of people in West Africa will be able to test the Ebola vaccine early next year.
A malaria vaccine in Phase II of a trial showed that after 4 years of injections, the protection effect against the disease was 0%, according to AFP on March 20.
According to a recent study, a combination of two Tykerb drugs and Herceptin will cause tumors to breast cancer patients before surgery.